“We are discussing another mechanism of motion that these drugs have in comparison with the outdated serotonergic compounds,” states Vermetten “The mechanism action doesn't count on 1 molecule.”This Viewpoint examines how US states are reforming legislation to allow access to psychedelics for therapeutic use, but federal regulations take in